AbbVie Inc (ABBV)vsCytosorbents Crp (CTSO)
ABBV
AbbVie Inc
$261.01
+3.99%
HEALTHCARE · Cap: $447.62B
CTSO
Cytosorbents Crp
$0.39
-5.94%
HEALTHCARE · Cap: $22.75M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 168768% more annual revenue ($62.82B vs $37.20M). ABBV leads profitability with a 5.8% profit margin vs -31.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CTSO
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.3%
Fair Value
$146.22
Current Price
$261.01
$114.79 premium
Intrinsic value data unavailable for CTSO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Trading at 9.8x book value
1.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : CTSO
CTSO has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : CTSO
The primary concerns for CTSO are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 8.64 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while CTSO is a turnaround play — different risk/reward profiles.
CTSO carries more volatility with a beta of 1.36 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 24/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Cytosorbents Crp
HEALTHCARE · MEDICAL DEVICES · USA
Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?